Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A

Haemophilia

Volumn 23, Issue 3, 2017, Pages 392-399

  Shapiro, A D ^a   Mahlangu, J N ^b   Perry, D ^c   Pasi, J ^d   Quon, D V ^e   Chowdary, P ^f   Tsao, E ^g   Li, S ^g   Innes, A ^g   Pierce, G F ^g   Allen, G A ^g  

^a INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e Orthopaedic Hemophilia Treatment Center   (United States)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g BIOGEN   (United States)

Author keywords

bleeding; factor VIII; haemophilia A; phase 3; prophylaxis; recombinant Fc fusion protein

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8 FC; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 8; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ARTICLE; BLEEDING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HEMOPHILIA A; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; SIMULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; COMPLICATION; FEMALE; GENETICS; SAFETY;

FACTOR VIII; FEMALE; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MALE; RECOMBINANT FUSION PROTEINS; SAFETY; TREATMENT OUTCOME;

EID: 85013389456     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13144     Document Type: Article

References (20)

1. World Federation of Hemophilia. Guidelines for the Management of Hemophilia. 2nd ed. Montreal, QC: World Federation of Hemophilia; 2012.
2. Collins PW, Blanchette VS, Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413–20.
3. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392–6.
4. Fogarty PF. Biological rationale for new drugs in the bleeding disorders pipeline. Hematology Am Soc Hematol Educ Program 2011; 2011: 397–404.
5. Mahlangu J, Powell JS, Ragni MV et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317–25.
6. Nolan B, Mahlangu J, Perry D et al. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia 2016; 22: 72–80.
7. Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost 2010; 8: 1895–902.
8. Cushman M. Inherited risk factors for venous thrombosis. Hematology Am Soc Hematol Educ Program 2005. doi: 10.1182/asheducation-2005.1.452.
9. Loeffen R, Spronk HMH, Ten Cate H. The impact of blood coagulability on atherosclerosis and cardiovascular disease. J Thromb Haemost 2012; 10: 1207–16.
10. Nestorov I, Neelakantan S, Ludden TM, Li S, Jiang H, Rogge M. Population pharmacokinetics of recombinant factor VIII Fc fusion protein. Clin Pharmacol Drug Devel 2015; 4: 163–74.
11. ® (internet). Seattle, WA: University of Washington, Seattle; 2000 (updated June 5, 2014).
12. Shapiro A, Gruppo R, Pabinger I et al. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. Expert Opin Biol Ther 2009; 9: 273–83.
13. Musso R, Santagostino E, Faradji A et al. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost 2008; 99: 52–8.
14. Recht M, Nemes L, Matysiak M et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 2009; 15: 869–80.
15. Lentz SR, Misgav M, Ozelo M et al. Results from a large multinational clinical trial (guardian1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013; 19: 691–7.
16. Allain JP. Dose requirement for replacement therapy in hemophilia A. Thromb Haemost 1979; 42: 825–31.
17. Aronstam A, Wasssef M, Choudhury DP, Turk PM, McLellan DS. Double-blind controlled trial of three dosage regimens in treatment of haemarthroses in haemophilia A. Lancet 1980; 1: 169–71.
18. Richards M, Williams M, Chalmers E et al. A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010; 149: 498–507.
19. Pipe S. Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A. Biologics 2009; 3: 117–25.
20. ELOCTATE ([Antihemophilic Factor (Recombinant) Fc Fusion Protein] Lyophilized Powder for Solution for Intravenous Injection) [package insert]. Cambridge, MA: Biogen; June 2014.